[go: up one dir, main page]

AR090582A1 - METODOS Y COMPOSICIONES PARA TRATAR CANCER USANDO ARNhc SRC 3 BIFUNCIONAL - Google Patents

METODOS Y COMPOSICIONES PARA TRATAR CANCER USANDO ARNhc SRC 3 BIFUNCIONAL

Info

Publication number
AR090582A1
AR090582A1 ARP130101077A ARP130101077A AR090582A1 AR 090582 A1 AR090582 A1 AR 090582A1 AR P130101077 A ARP130101077 A AR P130101077A AR P130101077 A ARP130101077 A AR P130101077A AR 090582 A1 AR090582 A1 AR 090582A1
Authority
AR
Argentina
Prior art keywords
src
compositions
methods
bifunctional
rna
Prior art date
Application number
ARP130101077A
Other languages
English (en)
Inventor
Lonard David
Senzer Neil
W Omalley Bert
J Nemunaitis John
Rao Donald
Wang Zhaohui
Original Assignee
Gradalis Inc
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gradalis Inc, Baylor College Medicine filed Critical Gradalis Inc
Publication of AR090582A1 publication Critical patent/AR090582A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones y métodos para elaborar y usar un vector de expresión que comprende un promotor y un inserto de ácido nucleico ligado operativamente al promotor, donde el inserto codifica uno o más ARN de horquilla corta (ARNhc) capaces de inhibir la expresión de un gen SRC-3 mediante interferencia de ARN, en donde dichos uno o más ARNhc comprenden una molécula de ARN bifuncional que activa un complejo de silenciamiento inducido por ARN dependiente del clivaje e independiente del clivaje para reducir el nivel de expresión de SRC-3 (coactivador del receptor nuclear 3), sistema de administración, método de administración, método para suprimir el crecimiento de un tumor.
ARP130101077A 2012-03-28 2013-04-03 METODOS Y COMPOSICIONES PARA TRATAR CANCER USANDO ARNhc SRC 3 BIFUNCIONAL AR090582A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261616873P 2012-03-28 2012-03-28

Publications (1)

Publication Number Publication Date
AR090582A1 true AR090582A1 (es) 2014-11-19

Family

ID=49235351

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101077A AR090582A1 (es) 2012-03-28 2013-04-03 METODOS Y COMPOSICIONES PARA TRATAR CANCER USANDO ARNhc SRC 3 BIFUNCIONAL

Country Status (4)

Country Link
US (1) US20130259925A1 (es)
AR (1) AR090582A1 (es)
TW (1) TW201346029A (es)
WO (1) WO2013148824A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661576A (zh) * 2014-04-25 2017-05-10 斯特里克生物公司 用于癌症治疗的多靶向RNAi
KR20230093329A (ko) 2020-10-28 2023-06-27 베이롤 칼리지 오브 메드신 암의 치료를 위한 면역조절 치료제로서 면역 세포에서 src-3의 표적화

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002346049A1 (en) * 2001-07-05 2003-01-21 Georgetown University Medical Center Coactivators in the diagnosis and treatment of breast cancer
WO2003089904A2 (en) * 2002-04-17 2003-10-30 Baylor College Of Medicine Aib1 as a prognostic marker and predictor of resistance to encocrine therapy
US8603991B2 (en) * 2005-11-18 2013-12-10 Gradalis, Inc. Individualized cancer therapy
US8252526B2 (en) * 2006-11-09 2012-08-28 Gradalis, Inc. ShRNA molecules and methods of use thereof
WO2008094516A2 (en) * 2007-01-29 2008-08-07 City Of Hope Multi-targeting short interfering rnas
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
GB2468477A (en) * 2009-03-02 2010-09-15 Mina Therapeutics Ltd Double stranded RNA molecule comprising siRNA and miRNA precursors
CA2772057C (en) * 2009-09-03 2016-02-02 Gradalis, Inc. Targeted delivery using tissue-specific peptidomimetic ligands
KR101543350B1 (ko) * 2009-10-30 2015-08-11 베이롤 칼리지 오브 메드신 Ｐｄｘ－１을 발현하는 신경내분비 종양에서 ｐｄｘ－１ 종양유전자를 표적화한 신규한 치료용 ｒｎａ 간섭 기법
US20110286979A1 (en) * 2010-05-20 2011-11-24 Gradalis, Inc. CHEMOSENSITIZATION BY BI-FUNCTIONAL SMALL HAIRPIN RNA (bi-shRNA)

Also Published As

Publication number Publication date
WO2013148824A1 (en) 2013-10-03
US20130259925A1 (en) 2013-10-03
TW201346029A (zh) 2013-11-16

Similar Documents

Publication Publication Date Title
CY1123355T1 (el) Αντισωματα εναντι cd73 και χρησεις εξ αυτων
SG10201811175WA (en) Method for treating cancer using a combination of chk1 and atr inhibitors
MX2025010269A (es) Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos
ECSP14013223A (es) Métodos para tratar el cáncer por el uso de antagonistas de unión al eje pd-1 e inhibidores de mek
MX2017008500A (es) Supresión del gen de la huntingtina inducida por la arni.
AR091004A1 (es) Arn en horquilla corta bifuncional (bi-arnhc) especifico de mutaciones de nucleotidos individuales en k-ras
MX2013008376A (es) Composiciones y metodos para el tratamiento de cancer.
PH12014502047A1 (en) Treatment of cancer with tor kinase inhibitors
CO2021008997A2 (es) Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de estos
MX2018013216A (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
CL2016003301A1 (es) Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma.
MX2017006942A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
MX364922B (es) Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer.
MX2016013600A (es) Método para tratar adenocarcinoma de pulmón.
EP4470617A3 (en) Pharmacophore for trail induction
DOP2014000199A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
BR112021025491A2 (pt) Métodos para uso de inibidores de rad51 para tratamento de câncer pancreático
CY1121859T1 (el) Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης
EP4335502A3 (en) Modified u6 promoter system for tissue specific expression
TN2016000114A1 (en) Compositions and methods for inhibiting expression of the alas1 gene.
MX2019011026A (es) Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer.
BR112017018861A2 (pt) métodos para tratar câncer mantendo perda hemizigótica de tp53
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.
AR090582A1 (es) METODOS Y COMPOSICIONES PARA TRATAR CANCER USANDO ARNhc SRC 3 BIFUNCIONAL
MX2016003248A (es) Metodos de uso de anticuerpos anti-lgr5.

Legal Events

Date Code Title Description
FB Suspension of granting procedure